Verastem (VSTM) Competitors $4.29 +0.14 (+3.37%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$4.35 +0.06 (+1.31%) As of 08:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VSTM vs. OPK, GERN, RGLS, MYGN, ZBIO, EBS, RIGL, XOMA, LXRX, and VNDAShould you be buying Verastem stock or one of its competitors? The main competitors of Verastem include OPKO Health (OPK), Geron (GERN), Regulus Therapeutics (RGLS), Myriad Genetics (MYGN), Zenas BioPharma (ZBIO), Emergent Biosolutions (EBS), Rigel Pharmaceuticals (RIGL), XOMA Royalty (XOMA), Lexicon Pharmaceuticals (LXRX), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "biotechnology" industry. Verastem vs. Its Competitors OPKO Health Geron Regulus Therapeutics Myriad Genetics Zenas BioPharma Emergent Biosolutions Rigel Pharmaceuticals XOMA Royalty Lexicon Pharmaceuticals Vanda Pharmaceuticals Verastem (NASDAQ:VSTM) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings. Do analysts prefer VSTM or OPK? Verastem presently has a consensus price target of $13.38, indicating a potential upside of 211.77%. OPKO Health has a consensus price target of $2.75, indicating a potential upside of 106.77%. Given Verastem's stronger consensus rating and higher possible upside, analysts plainly believe Verastem is more favorable than OPKO Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verastem 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00OPKO Health 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media prefer VSTM or OPK? In the previous week, Verastem had 10 more articles in the media than OPKO Health. MarketBeat recorded 14 mentions for Verastem and 4 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.52 beat Verastem's score of 0.31 indicating that OPKO Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OPKO Health 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, VSTM or OPK? OPKO Health has higher revenue and earnings than Verastem. OPKO Health is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerastem$10K23,573.55-$130.64M-$3.20-1.34OPKO Health$713.10M1.48-$53.22M-$0.07-19.00 Is VSTM or OPK more profitable? Verastem has a net margin of 0.00% compared to OPKO Health's net margin of -5.66%. OPKO Health's return on equity of -2.85% beat Verastem's return on equity.Company Net Margins Return on Equity Return on Assets VerastemN/A -2,003.62% -127.97% OPKO Health -5.66%-2.85%-1.82% Do insiders & institutionals believe in VSTM or OPK? 88.4% of Verastem shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 2.1% of Verastem shares are owned by company insiders. Comparatively, 49.7% of OPKO Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility & risk, VSTM or OPK? Verastem has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. SummaryVerastem and OPKO Health tied by winning 8 of the 16 factors compared between the two stocks. Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VSTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VSTM vs. The Competition Export to ExcelMetricVerastemMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$228.04M$2.85B$5.48B$8.94BDividend YieldN/A2.69%5.38%4.12%P/E Ratio-1.3421.1726.2119.74Price / Sales23,573.55262.85395.51109.12Price / CashN/A41.8936.4957.06Price / Book-6.607.237.915.37Net Income-$130.64M-$55.05M$3.15B$248.34M7 Day Performance-0.23%-0.60%0.77%1.67%1 Month Performance-28.74%3.77%3.46%4.56%1 Year Performance46.17%2.20%34.61%18.42% Verastem Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VSTMVerastem2.8181 of 5 stars$4.29+3.4%$13.38+211.8%+32.0%$228.04M$10K-1.3450High Trading VolumeOPKOPKO Health4.4444 of 5 stars$1.27-1.6%$2.75+116.5%+8.1%$1.01B$713.10M-18.142,997Positive NewsGERNGeron3.2776 of 5 stars$1.42-6.0%$5.06+256.5%-68.2%$904.43M$76.99M-6.7670RGLSRegulus Therapeutics2.0556 of 5 stars$8.14+3.3%$8.50+4.4%N/A$563.53MN/A-11.1530Gap UpHigh Trading VolumeMYGNMyriad Genetics4.4519 of 5 stars$4.86-1.2%$14.38+196.0%-76.9%$448.00M$837.60M-4.342,700ZBIOZenas BioPharma1.789 of 5 stars$9.47+3.0%$36.67+287.2%N/A$396.13M$5M-2.67N/APositive NewsEBSEmergent Biosolutions4.1952 of 5 stars$6.52+4.8%$14.33+119.8%-6.7%$353.91M$1.04B-2.412,420Gap DownRIGLRigel Pharmaceuticals2.8375 of 5 stars$18.84-0.5%$36.40+93.2%+122.5%$336.71M$203.08M9.10160XOMAXOMA Royalty4.4317 of 5 stars$26.22+9.0%$69.50+165.1%+5.8%$313.85M$28.49M-22.8010High Trading VolumeLXRXLexicon Pharmaceuticals2.5847 of 5 stars$0.73-2.1%$3.67+399.5%-47.2%$265.37M$31.08M-1.44140Gap DownVNDAVanda Pharmaceuticals4.6233 of 5 stars$4.47-0.9%$16.50+269.1%-16.1%$263.42M$198.77M-5.96290 Related Companies and Tools Related Companies OPKO Health Alternatives Geron Alternatives Regulus Therapeutics Alternatives Myriad Genetics Alternatives Zenas BioPharma Alternatives Emergent Biosolutions Alternatives Rigel Pharmaceuticals Alternatives XOMA Royalty Alternatives Lexicon Pharmaceuticals Alternatives Vanda Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VSTM) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
